All In Biotech

Drug Trial Radar · NCT06987097

Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension

Ambrisentan for the Treatment of Early-Stage Low-Risk Pulmonary Arterial Hypertension: A Multicenter, Randomized, Double-Blind, Placebo-Controlled ALEPH Trial

Last checked: Nov 20, 2026Latest source record: May 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 410 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

410

Planned (sponsor's estimate)

Start

May 15, 2025

Primary completion

Feb 28, 2028

Study completion Mar 1, 2029

Sponsor

Lead sponsor
Nanjing First Hospital, Nanjing Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled clinical trial.

Conditions

  • Pulmonary Arterial Hypertension (PAH)

Interventions

  • AmbrisentanDrug

    After two weeks of initial treatment, the study drugs' dose will be increased to two tablets per day (10 mg/day). If the patient cannot tolerate the increased dose (e.g., experiencing headache, dizziness, palpitations, hypotension, or other drug-related symptoms or signs), the dose will be reduced to 5 mg/day. If the study drug has reached the maximum allowable dose (two tablets/day) and the patient shows signs of worsening PAH or right heart failure, the clinician may decide to add diuretics (with the type and dosage left at the referring physician's discretion). The number and percentage of patients requiring diuretic combination therapy in both groups will be recorded. Other baseline treatment medications will remain unchanged through follow-up duration.

  • PlaceboDrug

    Placebo tablet (one to two tablets corresponding to one to two verum tablets). Administration: Placebo will be administrated orally with or without food intake in the morning.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary efficacy endpoint is the composite of pulmonary hypertension progression at 12 monthsTime frame: baseline,12 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.